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ttp://dx.doi.org/10.1016/j.ajpath.2013.10.028Hepatocellular carcinoma (HCC) represents one of the leading causes of cancer death and has proved to
be highly refractory to treatment. Extensive analysis of the disease has demonstrated that it arises
predominantly in response to high-risk etiological challenges, most notably hepatitis virus. However,
with evolving vaccination and the obesity epidemic, progressively more cases are associated with
underlying metabolic dysfunction. Pathologically diverse forms of HCC are observed, and recent
sequencing analysis has deﬁned common events that target well-known cancer pathways including b-
catenin/Axin, TP53, and RB/CDKN2A, as well as frequent aberrations in chromatin remodeling factors.
However, there are a myriad of low frequency genetic events that make each HCC case unique. Gene
expression proﬁling approaches have successfully been deployed for prognostic assessment of hepa-
tocellular carcinoma and to detect the earliest stages of disease. Despite more extensive research,
systemic treatment for HCC is exceedingly limited, with only a handful of drugs providing beneﬁt.
Ongoing clinical trials are attempting to exploit speciﬁc biological dependencies of HCC to improve the
dismal prognosis. Overall, the future of HCC treatment will rely on an understanding of the interplay
between etiological factors, molecular features of disease, and rational therapeutic intervention.
(Am J Pathol 2014, 184: 574e583; http://dx.doi.org/10.1016/j.ajpath.2013.10.028)Hepatocellular carcinoma (HCC), the most common type of
primary liver cancer, is the third leading cause of cancer-
related death worldwide.1 It is the ﬁfth most common cause
of cancer in men (7.9% of all cancers) and the seventh most
common cancer in women (6.5% of all cancers).2 There is
considerable geographic variation in HCC incidence, with
the majority of cases occurring in developing countries.
More than 75% of HCC occurs in Southeast Asia and sub-
Saharan Africa, with incidence rates exceeding 20 per
100,000 individuals. Southern European countries have in-
termediate incidence rates, whereas the lowest incidence
rates (<5 per 100,000 individuals) are found in North
America, South America, and Northern Europe.2Supported by grants from NIH (E.S.K.) and the Melanoma Research
Association (E.S.K.) and by contract funding from Pﬁzer (E.S.K.).
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E.S.K. is a consultant for Pﬁzer.Etiological Factors
Hepatitis B virus (HBV) is the primary etiological factor for
HCC worldwide, particularly in high-incidence areas, suchstigative Pathology.
.as Asia and Africa, where more than 70% of HCC patients
have underlying HBV infection.3 Annual incidence among
HBV carriers from Asia exceeds 0.2% starting at age 40;
therefore, HCC surveillance is recommended in Asian males
older than age 40 and Asian females older than age 50, even
in the absence of cirrhosis.4 Patients from Africa are
particularly at high risk, potentially related to a synergistic
effect from aﬂatoxin exposure, and experts recommend
HCC surveillance at an earlier age.5 HBV-infected patients
who are exposed to aﬂatoxin are 60 times more likely to
develop HCC compared to those with neither exposure,
which is likely related to HBV modulating the extent that
aﬂatoxins can bind to DNA and result in mutations in the
TP53 tumor-suppressor gene.6
Recent Advances in HCCIn Europe and the United States, hepatitis C virus (HCV)-
associated cirrhosis is the most common etiological factor,
accounting for approximately 60% of HCC cases.7 The risk
of HCC is increased 17-fold in HCV-infected patients
compared to HCV-negative patients.8 However, HCC risk
among patients with chronic HCV infection is primarily
limited to those with cirrhosis, with an annual incidence rate
of 2% to 8%.9,10 Alcoholic cirrhosis is another well-
recognized risk factor for HCC, and alcoholic liver disease
has been reported to be a contributing factor in nearly one-
third of all HCC cases worldwide.11,12 However, HCC
incidence rates among patients with alcoholic cirrhosis may
be overestimated, given that several studies linking alco-
holic cirrhosis and HCC predated routine testing for HCV
infection.
Nonalcoholic steatohepatitis (NASH) cirrhosis is antici-
pated to be the major etiological factor for HCC in the future,
as the number of NASH cases continues to increase in parallel
with the obesity and diabetes epidemics.13 Several studies
support an association between NASH and an increased risk of
HCC, although this risk appears to be limited primarily to
those with cirrhosis. Patients with NASH, but no cirrhosis,
typically have cumulative HCC mortality rates of <1%,
whereas those with NASH-related cirrhosis have cumulative
HCC incidence rates of 2.4% to 12.8%.14
Most recent reports suggest that the incidence of HCC in
high- and intermediate-incidence areas may be stabilizing or
falling.2 In China and Taiwan, this is related to more wide-
spread HBV vaccination programs and higher rates of HBV
treatment.15 In Japan and Southern Europe, the decrease in
HCC incidence may relate to an aging cohort of patients with
HCV infection.16,17 In contrast, the incidence of HCC in low-
incidence areas, such as the United States, is rapidly
increasing. In the 10-year period from 1995 to 2004, HCC
had the largest increase in incidence among all solid tumors
in the United States.18 The rising incidence of HCC in the
United States is related to several factors, but the two most
important are growing populations of patients with advanced
HCV infection and NASH.2 In parallel with its rising inci-
dence rate, HCC also has one of the fastest growing death
rates among solid tumors. Whereas the prognosis for most
solid cancers improved over the 10-year period from 1994 to
2003, the mortality rate for HCC nearly doubled.7,18Table 1 Patient Populations inWhom Surveillance Is Recommended
Surveillance Recommended
Asian male hepatitis B carrier older than age 40
Asian female hepatitis B carrier older than age 50
African Blacks with hepatitis B
Hepatitis B carrier with family history of HCC
Cirrhosis from any etiology
Surveillance Beneﬁts Uncertain
Asian hepatitis B carriers younger than age 40 (males) or
younger than age 50 (females)
Hepatitis B carriers who contracted infection via horizontal
transmission
Hepatitis C carriers without cirrhosis
Nonalcoholic fatty liver disease patients without cirrhosisSurveillance and Early Detection
Because many patients with HCC are asymptomatic when
tumors are at an early stage, routine surveillance in patients
with cirrhosis is important (Table 1). Although predictive risk
models have been created to better deﬁne a high-risk sub-
group among cirrhotic patients, none have been externally
validated or ready for routine use in clinical practice.19,20
Ultrasound is the most widely used radiological test for
HCC surveillance.21 The sensitivity of ultrasound for early
stage HCC is only 63% (95%CI 49% to 76%), meaning moreThe American Journal of Pathology - ajp.amjpathol.orgthan one-third of all tumors are missed or diagnosed at
advanced stages.22 Although a fetoprotein (AFP) was
included as an adjunct surveillance test to ultrasound in prior
guidelines, there has been increasing debate regarding its
usefulness in surveillance.23e27 Recent data suggest that AFP
may improve the effectiveness of surveillance for detecting
early HCC in clinical practice, increasing sensitivity from
<50% for ultrasound or AFP alone to nearly 65% when the
two tests are combined.26 Other tumor biomarkers that have
been evaluated include des-g-carboxy prothrombin and the
lens culinaris-agglutinin reactive fraction of AFP (APF-
L3%)28; however, a large multicenter study demonstrated
that AFP may be more sensitive for early stage HCC than
either of these two biomarkers.29 Glypican 3,30,31 GP73,32
osteopontin,33 squamous cell carcinoma antigen,34 human
hepatocyte growth factor,35 and insulin growth factor-1,36 are
examples of other biomarkers that are being evaluated, but
data are preliminary and require validation in large cohorts.
The ﬁeld of proteomics may also provide tools to determine
other novel serum biomarkers in HCC in the future.37Pathological Features of HCC and Clinical
Prognostic Tools
Effective radiological methods can yield a diagnosis of
HCC; however, pathological evaluation remains a key
aspect of clinical management. Microscopically, HCC tends
to resemble normal hepatocytes, depending on the degree of
differentiation, and architecture within the tumor can reca-
pitulate normal liver architecture in the early stages,
mimicking normal liver cell plates. Most commonly, HCC
produces acinar, pseudoglandular, trabecular, and solid
growth patterns, often with multiple growth patterns within
a single tumor (Figure 1). As the tumor progresses, the
preservation of architecture is lost, with crowding and high
nuclear to cytoplasmic ratio. When HCC arises in a back-
ground of cirrhosis, distinguishing characteristics of the
underlying disease are not present sometimes, which is due
to altered landmarks and vascular relationships; however,
histological changes in the surrounding cirrhotic liver can575
Figure 1 A: H&E staining for hepatocellular carcinoma, pseudo-
glandular growth pattern. B: Hepatocellular carcinoma, trabecular growth
pattern. C: Hepatocellular carcinoma, solid growth pattern. Original
magniﬁcation: 20 (A); 40 (B and C).
Figure 2 A: H&E staining for hepatocellular carcinoma arising in NASH
with prominent intratumoral steatosis, chronic inﬂammation, and rare
ballooned tumor cells containing Mallory-Denk bodies. B: Hepatocellular
carcinoma arising in NASH with ballooned tumor cells containing prominent
Mallory-Denk bodies. Original magniﬁcation, 40 (A and B).
Knudsen et aloften provide a clue to the etiology of the cirrhosis and
HCC. NASH and alcoholic liver disease have several
histological similarities, including steatosis, ballooning
degeneration of hepatocytes, Mallory-Denk bodies, peri-
cellular ﬁbrosis, and mixed lobular inﬂammation. Typical
histological ﬁndings of HCV infection include portal lym-
phoplasmacytic inﬂammatory inﬁltrate, occasionally with576prominent lymphoid aggregates, and variable lobular
inﬂammation. Histological ﬁndings of HBV can overlap
with HCV, but ground glass hepatocytes are a distinctive
histological feature that can help distinguish cases of HBV
infection. Several recent studies have described a steatohe-
patitic variant of HCC that can be seen in patients with HCC
related to steatohepatitis (NASH and/or alcoholic liver dis-
ease).38e41 This HCC variant is described as having
steatohepatitis-like features within the tumor, including
steatosis, ballooning degeneration of the malignant hepato-
cytes, intratumoral pericellular ﬁbrosis, Mallory-Denk
bodies, and inﬂammation (Figure 2). In a study by Salo-
mao et al,40 36% of patients who developed HCC in the
setting of steatohepatitis were diagnosed as having a stea-
tohepatitic variant of HCC as compared to 1.3% of HCC
patients without steatohepatitis. Immunohistochemically,
there was diffuse loss of cytoplasmic CK8/18 and an
increased number of activated hepatic stellate cells with the
steatohepatitic HCC, identical to the pattern seen in the
surrounding nonneoplastic liver.40ajp.amjpathol.org - The American Journal of Pathology
Recent Advances in HCCPatients with NASH-related HCC often have less severe
liver dysfunction at HCC diagnosis and may have better
overall survival after curative treatments than their coun-
terparts with HCV and/or alcohol-related cirrhosis.42 How-
ever, studies speciﬁcally evaluating steatohepatitic HCC
have not found any difference in prognosis compared to
conventional HCC, including similar rates of distant me-
tastases, local recurrence, or overall survival.40
Although there is histological variation between HCC
cases, these variations are not routinely used in treatment
decision-making. In general, treatment decisions are based
on the Barcelona Clinical Liver Cancer staging system,
which has been validated in several large cohort studies.43,44
In essence, this staging system incorporates information
related to liver function (Child-Turcotte-Pugh Score), per-
formance status, and tumor burden. This staging system is
unique in that it has been linked to a treatment algorithm and
can be used to triage patients to potentially curative treat-
ments (ie, resection, transplant, ablation) versus chemo-
embolization versus systemic therapies. It is clear that
additional factors could further enhance its prognostic
ability, which has spurred the investigation of HCC mo-
lecular features that could better portend prognosis or deﬁne
new opportunities for therapy.Genetic Underpinnings of HCC
It is clear that diverse etiological stresses play a key role in
the etiology of HCC. However, the prevailing view is that
liver damage drives aberrant cycles of proliferation in theFigure 3 Multiple etiological events drive liver cirrhosis. This results in multip
the development of genetic and epigenetic alterations. Complex combinations of t
can be treated with locoregional therapies, but systemic approaches are relatively
HBV, hepatitis B virus; HCV, hepatitis C virus.
The American Journal of Pathology - ajp.amjpathol.orgcontext of inﬂamed cirrhotic liver tissue leading to the
accumulation of genetic changes that ultimately drive
transformation of target cells to HCC (Figure 3).45 Although
conventional targeted analyses of speciﬁc markers in the
HCC have been performed and have identiﬁed key path-
ways of signiﬁcance to the etiology,46,47 unbiased molecular
approaches have provided an opportunity to decipher key
pathways and genetic events in disease and their connection
to the underlying etiologies. Particularly, utilization of gene
expression proﬁling and next generation sequencing tech-
nologies provide a portrait of common molecular events that
occur in the pathogenesis of HCC.
At present, the sequencing of exons in approximately 100
HCC cases has been performed (Table 2).48e52 It should be
noted that although an important effort from multiple
groups, this pales in reference to other diseases, wherein
>1000 tumors have been sequenced. However, these studies
have yielded a wealth of information in reference to genetic
architecture of HCC and key pathways that are likely rele-
vant to the development of HCC.
One of the seminal advantages of next generation
sequencing is the ability to deﬁne new mediators of hep-
atocarcinogenesis, and the analyses of data have revealed
several key previously unknown features of disease and
important new pathways that are likely of high relevance in
HCC. An important and often underappreciated aspect of
sequencing is the ability to deﬁne mutation spectra (eg, C to
T transitions) that are particularly prevalent in the disease.
Many tumor types have distinct spectra that are associated
with disease etiology. For example, lung cancers have
C/A, which are speciﬁcally associated with smoking,le cycles of compensatory proliferation and inﬂammation, which can drive
hese events are associated with the development of HCC. Early stage disease
limited at present. Multiple investigational drugs are under investigation.
577
Table 2 Studies with Exon Sequencing of HCC Cases
Common mutations Cases (n) Etiology References
CTNNB1 (11%)
TP53 (52%)
ARID1A (19%)
27 HBV/HCV 50
CTNNB1 (16%)
TP53 (35%)
88 HBV 51
TP53 (10%)
ARID1A (10%)
ARID2 (10%)
10 HBV 49
CTNNB1 (46%)
TP53 (13%)
AXIN1 (21%)
ARID1A (17%)
24 50% alcohol
HBV/HCV
48
Knudsen et alwhereas melanoma has CC/TT dinucleotide substitutions
that would be associatedwith exposure to solar radiation.53e55
To date, sequencing has been performed largely on cases with
a viral (HBV or HCV) or alcohol-related etiology.48e52 In this
context, HCC has a relatively uniquemutation spectra, G/T,
which is apparently modiﬁed by the etiological basis of dis-
ease, with HCC arising in cirrhotic livers exhibiting differen-
tial mutational events relative to noncirrhotic livers.48
However, with the relatively small number of samples, it is
difﬁcult to discern if different etiological stresses are associ-
ated with speciﬁc genetic events. Additionally, to date, no
signiﬁcant cohorts with aﬂatoxin B1- or NASH-associated
tumors have been sequenced; therefore, whether the different
mechanisms associated with HCC development will yield
distinct genetic alterations remains unknown.
As one may expect, sequencing should identify expected
oncogenes and tumor suppressors. The most commonly
deﬁned mutated oncogenic driver of HCC is the b-catenin
gene (CTNNB1).48e51 This is a validated oncogene that has
been previously implicated in HCC pathogenesis from tar-
geted analyses of human tissue and the use of mouse
models.56 Further implicating the importance of this
pathway, loss of Axin1 and Axin2, which are negative
regulators of b-catenin, are also frequently observed in
HCC.48e51 Similarly, TP53 has been identiﬁed as a
frequently mutated tumor suppressor in HCC.48e51 Again,
this is consistent with established analysis of human tumorTable 3 HCC Subtypes Identiﬁed by Gene Expression Proﬁling Approa
Subtypes Genes/Processes
A and B Multiple/proliferation
CIN: high and low Proliferation
G1-G6 Multiple/proliferation
RB-loss: high and low Proliferation
A, B, and C Multiple/proliferation
65 genes Multiple
5-gene score HN1, RAN, RAMP3, KRT19, and TA
186-gene signature Nontumor liver
CIN, chromosome instability signature.
578specimens. Surprisingly, TP53 itself is a weak tumor sup-
pressor in mouse models, and largely cooperates with other
stresses in suppressing the development of HCC or cur-
tailing the metastatic potential of HCC models.57,58 These
ﬁndings reinforce the importance of investigating human
tissue to truly understand the underpinnings of human dis-
ease. Because exome or whole genome sequencing is a
discovery platform, it was an important ﬁnding that multiple
chromatin modiﬁers of the SWI/SNF family are associated
with HCC.48e51 Loss of these tumor suppressors is rela-
tively common across multiple solid tumors.59 Importantly,
in such analyses, although Arid1A and Arid2 mutations are
particularly prevalent in HCC, multiple genes in the SWI/
SNF chromatin remodeling complex are mutated. However,
the functional signiﬁcance of such alterations remains
obscure relative to the etiology or progression of HCC. A
large number of additional genes involved in discrete
carcinogenic processes involved in carcinogenesis were
found to be mutated in HCC. For example, composite mu-
tations/loss of cell cycle regulatory genes CDKN2A and
RB1, disruption of genes involved in chromosome stability
such as ATM and MLH1, and genes that mediate epigenetic
regulation, such as MLL3 and MLL, have all been found to
be mutated in HCC.48e51 Although these data yield some
insight into the genetics of HCC, the lack of commonality
between individual cancer cases is most striking. This
contrasts with tumors like pancreatic cancer in which veri-
tably of all cases harbor well-known oncogenic drivers (ie,
K-ras). These data underline one of the unique features of
HCC in that it is highly heterogeneous. Given this same
heterogeneity it remains unclear how such genetic ﬁndings
will yield actionable insights on which disease treatment can
be modiﬁed to improve patient outcomes.
Gene Expression Proﬁling Prognostic Markers
and Pathways
In contrast with the seemingly inﬁnite diversity of HCC as
shown by sequencing, gene expression proﬁling approaches
monitoring changes in RNA levels on microarray platforms
have deﬁned a limited series of HCC subtypes (Table 3).ches
Clinical endpoint References
Overall survival 61
Overall survival 64
Overall survival 67
Overall survival 63
Overall survival 65
Overall survival 72
F9 Overall survival
End-stage disease
70
Overall survival
Risk of recurrence
69
ajp.amjpathol.org - The American Journal of Pathology
Recent Advances in HCCEarly work from Dr. Thorgeirrson’s group deﬁned gene
expression changes in HCC cases related to proliferation
and other core features of disease that were associated with
prognosis.60e63 These ﬁndings were recapitulated from
numerous groups demonstrating that tumors with elevated
expression of proliferation-associated genes were prognostic
for poor outcome dependent on methodology.34,63e66
Additional analyses served to deﬁne subgroups. Specif-
ically, HCC can be classiﬁed into three or six subtypes
based on gene expression proﬁling.65,67 These groups are
consistent across multiple independent cohorts and have
differential overall prognosis.65 This work was similar to
that performed in breast cancer68 and is important for clar-
ifying intrinsically different forms of HCC that have distinct
prognosis. Such multigene signatures have been distilled to
inform progression of early stage disease and vascular
invasion.31,69e72 Most recently, extensive analysis of clin-
ical specimens by gene expression proﬁling deﬁned a 5-
gene signature.70 This signature was effective in both
training and validation sets and outperformed other signa-
tures that have been previously identiﬁed for determining
the risk of recurrence and death after disease resection.
Analysis of the nontumor liver tissue also provides impor-
tant prognostic information. A 186-gene signature is asso-
ciated with poor prognosis of early stage disease and risk of
disease progression in the cirrhotic liver.69 Presumably, this
is because the tissue is reﬂective of the carcinogenic milieu
within the liver, and thus it is associated with risk of poor
clinical outcome. Although multiple signatures appear
prognostic in retrospective analysis, there remain no estab-
lished predictive markers that have been shown to improve
patient treatment. Thus, although there are newly deﬁned
subtypes of HCC based on gene expression proﬁles, these
markers have yet to yield directed treatments for HCC.Targeted Therapeutic Interventions: A Work in
Progress
Despite substantial and accelerated research in the area of
HCC, the 5-year survival for advanced disease remains
<10%.73e75 Localized disease can be treated with ablative
therapies, surgical resection, or transplantion.75e77 How-
ever, many cases present at the advanced stage or the patient
is a poor candidate for such interventions. Thus, substantial
clinical research has been conducted to provide improved
treatment for HCC with systemic therapies. Phase III trials
have evaluated multiple therapeutic modalities, including
tamoxifen, chemotherapy, and interferon, all with negative
outcomes.76,78,79 The lack of beneﬁt with multiple chemo-
therapy regimens makes HCC somewhat unique in cancer
by having no standard cytotoxic therapy, and indicates that
HCC must be treated by other targeted agents.80e82 The only
drug approved for advanced HCC is the multikinase inhib-
itor sorafenib. In HCC, sorafenib functions as a cytostatic
agent that provides an approximate 3-month improvement inThe American Journal of Pathology - ajp.amjpathol.orgsurvival versus placebo control based on large randomized
phase III trial versus placebo.83 Despite the positive impact
on survival, HCC remains a classical therapy recalcitrant
disease for which new interventions are needed.
Multiple ongoing phase II and phase III trials support the
possible development of new treatment opportunities for
advanced HCC.78,84 The majority of phase II trials represent
approaches to deﬁne positive effect of treatment with
progression-free survival as the primary endpoint.85,86
These studies build off of the clinical outcomes with sor-
afenib and are often conducted in the second line (after
sorafenib failure) or as a ﬁrst-line agent in combination with
sorafenib.84 A number of agents have shown promise in this
context including brivanib and bevacizumab-erlotinib.87e90
Because of the advanced nature of HCC and the underly-
ing liver disease and underlying liver disease associated
with late stage HCC, the outcomes have been relatively
modest. Interestingly, sorafenib, brivanib, and bevacizumab
all targeted VEGF signaling, suggesting that this may be an
important therapeutic node in HCC. Based on the identiﬁ-
cation of multiple additional key pathways disrupted in
HCC, trials have been rationally directed to target common
oncogenic events. For example, with the key role of Met
signaling in HCC, the drug tivantinib has been investigated
in a randomized phase II trial.91,92 Similarly, given the
frequent loss of CDKN2A and deregulation of the retino-
blastoma tumor suppressor pathway, the CDK4/6 inhibitor
PD-0332991 is being tested in advanced HCC (http://
clinicaltrials.gov, Clinical Trial NCT01356628). These tri-
als and further multiple, additional trials will likely shed
light on agents that have potential usefulness in HCC. A
critical aspect of such targeted therapies is the importance of
deﬁning features of disease that underlie sensitivity to the
agent. For example, in retrospective analysis, tivantinib is
particularly effective against HCC, which has a high
expression of Met.91,92 Therefore, it will be important to
leverage the molecular analyses of HCC to delineate speciﬁc
subtypes of HCC or individual cases that would be partic-
ularly responsive to a given therapeutic regimen.Challenges and Future Directions
HCC represents a particular challenge for which there is
multiple opportunities to change the large burden of disease
and terrible prognosis.Prevention
Because etiological features of HCC are very well-deﬁned,
it represents a disease for which preventive strategies could
be particularly effective. Ostensibly, these etiologies can be
ultimately controlled, thereby substantially reducing the
number of individuals at high risk for HCC. The decreasing
incidence of HCC in Asia speaks to the potential beneﬁts
and promise of preventive measures, such as HBV579
Knudsen et alvaccination and treatment.93 Although a vaccine for HCV
does not exist, successful treatment has been associated with
signiﬁcant reductions in HCC risk.94 The introduction of
interferon-free treatment regimens, with better success rates
and lower toxicity rates, may further expand HCV treatment
rates and help to reduce the future burden of HCC.95 Given
the increasing prevalence of NASH-related HCC, studies
assessing the potential impact of weight loss, either via diet
and exercise or bariatric surgery, are necessary. Finally,
larger studies assessing the potential preventive beneﬁt of
diet, coffee, and statins are necessary.96,97
Early Detection
Because the etiological factors of HCC can be deﬁned rela-
tively easily in the clinic, it is surprising that the diagnosis of
HCC often occurs at such a late stage.18 This failure is related
to several reasons, including underutilization of surveillance,
delayed follow-up of surveillance tests, and suboptimal
effectiveness of surveillance tests. Several studies have
demonstrated that <20% of patients with cirrhosis receive
HCC surveillance, as recommended by guidelines.98e100
Underutilization of HCC surveillance is related to multiple
failure points, including under-recognition of liver disease,
under-recognition of cirrhosis, and physicians failing to order
HCC surveillance in patients with known cirrhosis, high-
lighting a need for multifaceted interventions to improve
cirrhosis recognition and facilitate HCC surveillance
testing.101 However, a secondary analysis of the Hepatitis C
Antiviral Long-term Treatment Against Cirrhosis (HALT-C)
trial suggested that the most common reason for late stage
tumor presentation is related to poor sensitivity of currently
available surveillance tools.102 Therefore, it is critically
important to develop markers that are easily used that have a
high sensitivity and speciﬁcity for the detection of early stage
disease. Such markers could then provide the trigger for
radiological imaging to identify early stage disease in which
resection or ablative therapies can be more effective.
Fully Understanding the Genetic Diversity
For HCC, sequencing analysis has served to provide a better
understanding of the tumor genetics. However, these data
have also demonstrated that no HCC tumor is alike, and
only a minority of cases has a mutation that would imme-
diately provoke a speciﬁc therapeutic approach. Therefore,
the challenge is to understand how genetics can be used to
provide a road map for the treatment of HCC.
Dissecting the Therapeutic Sensitivities of HCC
Subtypes
At present, HCC cases are treated similarly with little
consideration of molecular subtypes or markers that could
be relevant to prognosis or therapeutic sensitivities. There is
clearly an opportunity to deﬁne markers predictive of580response to speciﬁc agents to begin reﬁning the treatment
paradigm for HCC from a one size ﬁts all to one of more
precision-guided therapy. The emerging trials with tivanti-
nib will provide the ﬁrst indication that stratifying patients
to speciﬁc treatment regimens will perhaps improve care.91
Implementing More Effective Treatment
The dismal prognosis of advanced HCC provides a seminal
opportunity for improved treatment options. The plethora of
ongoing early stage trials provides hope for more effective
regimens, although it will be critically important to consider
the incredible diversity of HCC when investigating thera-
peutic response. Clinicians should be cognizant of the op-
portunity that is provided by analyzing tissue from such
trials to better inform future clinical interventions and to
avoid making broad conclusions on an unselected patient
population, wherein the expectation should be likely that
only a subset of patients would experience a favorable
response to the intervention.
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